Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
917 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01466660 | LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung | completed | Phase 2 | 319 | Boehringer IngelheimINDUSTRY | 14 | Apr 7, 2020 | clinicaltrials |
| NCT01507168 | A Study of GC33 (RO5137382) in Patients With Advanced or Metastatic Hepatocellular Carcinoma | completed | Phase 2 | 185 | Hoffmann-La RocheINDUSTRY | 13 | Apr 3, 2020 | clinicaltrials |
| NCT02401542 | Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma(FIERCE-21) | terminated | Phase 1 / Phase 2 | 71 | Rainier TherapeuticsINDUSTRY | 9 | Mar 9, 2020 | clinicaltrials |
| NCT02544633 | Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET | completed | Phase 2 | 68 | Mirati Therapeutics Inc.INDUSTRY | 9 | Mar 4, 2020 | clinicaltrials |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 5 | Feb 26, 2020 | clinicaltrials |
| NCT01503346 | DaHuang GangTsao Tang to Improve the Appetite Loss Condition of Cancer Patients(TCM) | completed | Phase 2 | 4 | Changhua Christian HospitalOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01796821 | Efficacy and Safety Profiles of SR-T100 Gel on External Genital Warts/Condyloma Acuminate(EGWs) | completed | Phase 2 | 138 | G&E Herbal Biotechnology Co., LTDINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT02289300 | A Study to Evaluate a Study Drug, DCB-BO1202, for Alleviating Liver Fibrosis in Liver Cancer Patients | withdrawn | Phase 2 | 0 | A2 Healthcare Taiwan CorporationINDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT02047344 | Efficacy, Safety and Pharmacokinetics Study of Antroquinonol to Treat NSCLC | completed | Phase 2 | 31 | Golden Biotechnology CorporationINDUSTRY | 2 | Dec 26, 2019 | clinicaltrials |
| NCT00263588 | Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer | completed | Phase 2 | 242 | Novartis PharmaceuticalsINDUSTRY | 17 | Dec 12, 2019 | clinicaltrials |
| NCT02981342 | A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma | completed | Phase 2 | 106 | Eli Lilly and CompanyINDUSTRY | 8 | Nov 20, 2019 | clinicaltrials |
| NCT01602224 | A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM) | completed | Phase 2 | 220 | Eli Lilly and CompanyINDUSTRY | 15 | Oct 8, 2019 | clinicaltrials |
| NCT00988858 | A Study of Advanced or Metastatic Non-small Cell Lung Cancer | completed | Phase 2 | 55 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 17, 2019 | clinicaltrials |
| NCT01469000 | A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 195 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 10, 2019 | clinicaltrials |
| NCT00813163 | Study of PEP02 as a Second Line Therapy for Metastatic Pancreatic Cancer | completed | Phase 2 | 41 | PharmaEngineINDUSTRY | 2 | Sep 6, 2019 | clinicaltrials |
| NCT02425137 | A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer | completed | Phase 2 | 51 | TTY BiopharmINDUSTRY | 1 | Aug 21, 2019 | clinicaltrials |
| NCT01877083 | Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung | completed | Phase 2 | 25 | Eisai Inc.INDUSTRY | 5 | Aug 13, 2019 | clinicaltrials |
| NCT04035096 | The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT01646125 | An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations | terminated | Phase 2 | 59 | Novartis PharmaceuticalsINDUSTRY | 12 | Jul 24, 2019 | clinicaltrials |
| NCT03207139 | Ga-68 PSMA Ligand: A Radiopharmaceutical for Localization of Prostate Cancer | completed | Phase 2 | 71 | Chang Gung Memorial HospitalOTHER | 1 | Jul 17, 2019 | clinicaltrials |
| NCT02023697 | Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone | completed | Phase 2 | 391 | BayerINDUSTRY | 15 | Jul 12, 2019 | clinicaltrials |
| NCT01271725 | LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment Failures | completed | Phase 2 | 74 | Boehringer IngelheimINDUSTRY | 6 | Jun 17, 2019 | clinicaltrials |
| NCT02186301 | TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy(EGFR) | terminated | Phase 2 / Phase 3 | 100 | Clovis Oncology, Inc.INDUSTRY | 7 | May 7, 2019 | clinicaltrials |
| NCT00912275 | Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 46 | National Taiwan University HospitalOTHER | 1 | May 6, 2019 | clinicaltrials |
| NCT02457273 | Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients | completed | Phase 2 | 23 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 3, 2019 | clinicaltrials |
| NCT01685138 | LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer | completed | Phase 2 | 124 | Novartis PharmaceuticalsINDUSTRY | 18 | Mar 26, 2019 | clinicaltrials |
| NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 72 | Tesaro, Inc.INDUSTRY | 5 | Mar 26, 2019 | clinicaltrials |
| NCT02606097 | Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation | completed | Phase 2 | 19 | Chang Gung Memorial HospitalOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT03880877 | Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer | unknown | Phase 2 | 153 | Kaohsiung Medical University Chung-Ho Memorial HospitalOTHER | 1 | Mar 21, 2019 | clinicaltrials |
| NCT02472145 | An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | completed | Phase 2 / Phase 3 | 326 | Janssen Research & Development, LLCINDUSTRY | 14 | Mar 19, 2019 | clinicaltrials |
| NCT01685983 | A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer | completed | Phase 2 | 82 | Janssen Research & Development, LLCINDUSTRY | 2 | Mar 15, 2019 | clinicaltrials |
| NCT02423811 | Fursultiamine in Esophageal Squamous Cell Carcinoma Patients Who Receive Concurrent Chemoradiotherapy | completed | Phase 2 | 20 | National Cheng-Kung University HospitalOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT03711240 | The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases(CBL) | unknown | Phase 2 | 40 | National Cheng-Kung University HospitalOTHER | 1 | Mar 13, 2019 | clinicaltrials |
| NCT02812641 | Neoadjuvant CCRT With/Without Bevacizumab for Locally Advanced ESCC | unknown | Phase 2 | 50 | National Taiwan University HospitalOTHER | 1 | Mar 11, 2019 | clinicaltrials |
| NCT02267213 | Efficacy and Safety Study of TLC388 to Advanced Hepatocellular Carcinoma | terminated | Phase 2 | 29 | Taiwan Liposome CompanyINDUSTRY | 2 | Feb 26, 2019 | clinicaltrials |
| NCT01376310 | GSK1120212 Rollover Study | terminated | Phase 2 | 159 | Novartis PharmaceuticalsINDUSTRY | 6 | Feb 19, 2019 | clinicaltrials |
| NCT03121313 | Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+ | unknown | Phase 2 | 68 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2019 | clinicaltrials |
| NCT02828124 | A Study of the Safety and Tolerability of BMS-986183 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 4 | Jan 30, 2019 | clinicaltrials |
| NCT02191878 | Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 43 | Arbutus Biopharma CorporationINDUSTRY | 6 | Jan 16, 2019 | clinicaltrials |
| NCT01210495 | Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma | completed | Phase 2 | 224 | PfizerINDUSTRY | 13 | Jan 9, 2019 | clinicaltrials |
| NCT00818441 | Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung | completed | Phase 2 | 119 | PfizerINDUSTRY | 5 | Jan 8, 2019 | clinicaltrials |
| NCT02269943 | Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 36 | CelgeneINDUSTRY | 9 | Dec 12, 2018 | clinicaltrials |
| NCT03035006 | Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis | terminated | Phase 1 / Phase 2 | 1 | Taiwan Liposome CompanyINDUSTRY | 1 | Nov 6, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT02811354 | Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA(PLASMA) | unknown | Phase 2 | 108 | National University Hospital, SingaporeOTHER | 5 | Sep 20, 2018 | clinicaltrials |
| NCT01910025 | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy | completed | Phase 2 | 18 | Polaris GroupINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01310036 | A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 4 | Sep 12, 2018 | clinicaltrials |
| NCT02006030 | Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma(TACE) | completed | Phase 2 | 30 | Polaris GroupINDUSTRY | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01727089 | Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 59 | National Cancer Institute (NCI)NIH | 3 | Aug 28, 2018 | clinicaltrials |
| NCT00915018 | Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer(NEFERTT) | completed | Phase 2 | 479 | Puma Biotechnology, Inc.INDUSTRY | 35 | Aug 22, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials